Is Generation Bio Co (GBIO) overvalued? · rev $19.9M
Generation Bio Co (GBIO) is a biotechnology company listed on US.
This page asks whether Generation Bio Co (GBIO) looks expensive on cached numbers — not a short thesis.
Latest reported GBIO revenue for 2024-12-31 was $19.9M. Net income was -$131.7M. Revenue was up 236.9% from 2023-12-31 to 2024-12-31. GBIO currently screens at market cap $25.4M.
GBIO currently screens at market cap $25.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GBIO stock page for the full model, not this heading.
Not investment advice.